Dexamethasone Fails in Real World Study of Hospitalized Acute COVID-19
Half of Treated Patients Die on Medication when Noninvasive Pressure or Mechanical Assisted Ventilation Required
By Peter A. McCullough, MD, MPH
One of the oddest therapies to come forward during the COVID-19 pandemic was dexamethasone (a glucocorticoid used for cerebral edema) at 6 mg per day for acute treatment. I have used steroids for acute pulmonary conditions my entire career and routinely use much higher and frequent doses of the balanced steroid prednisone or methylprednisolone in 60 mg 120 mg doses depending on the situation. In the outpatient McCullough Protocol the dose of prednisone is 40 mg a day. So when dexamethasone 6 mg was chosen in the original RECOVERY trial and the treated mortality rate was 22.9%, I knew it was the wrong steroid at the wrong dose.
Keep reading with a 7-day free trial
Subscribe to Courageous Discourse™ with Dr. Peter McCullough & John Leake to keep reading this post and get 7 days of free access to the full post archives.